Product image of Icatibant Stada (Icatibant) supplied by GNH India

Icatibant Stada

Active Ingredient:
Icatibant
Origin:
EU

Icatibant Stada (Icatibant)

Icatibant, the active ingredient in Icatibant Stada, is a bradykinin B2 receptor antagonist presented as a solution for injection for subcutaneous use. It treats acute attacks of hereditary angioedema type I and type II in patients with this condition.

GNH India supplies Icatibant Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Stada Arzneimittel Ag

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Icatibant is a targeted therapy for hereditary angioedema that works by blocking the bradykinin B2 receptor pathway.

  • Acute hereditary angioedema type I: provides rapid relief of swelling during an attack.
  • Acute hereditary angioedema type II: reduces the severity and duration of edema episodes.
  • Hereditary angioedema of any type: helps control life‑threatening airway obstruction when administered promptly.

How It Works

  • Icatibant selectively binds to the bradykinin B2 receptor, preventing bradykinin from activating the receptor. This inhibition blocks the downstream signaling that leads to vasodilation and increased vascular permeability, thereby reducing the swelling characteristic of hereditary angioedema attacks.

Side Effects

Common Side Effects

  • Injection site pain: discomfort at the subcutaneous injection site.
  • Redness or swelling at injection site: mild local reaction.
  • Nausea: transient feeling of queasiness.
  • Headache: mild to moderate headache.
  • Dizziness: temporary light‑headedness.
  • Fatigue: general feeling of tiredness.

Serious or Rare Side Effects

  • Anaphylactic reaction: severe allergic response requiring immediate medical attention.
  • Airway angioedema: swelling of the throat or tongue that may compromise breathing.
  • Severe hypotension: sudden drop in blood pressure.
  • Urticaria: widespread hives.
  • Necrosis at injection site: tissue death at the injection area.
  • Thrombocytopenia: low platelet count observed in rare cases.

Precautions & Warnings

Before using Icatibant, consider the following precautions:

  • Pregnancy: safety not established; use only if the potential benefit justifies the risk.
  • Breastfeeding: unknown effects on the infant; weigh benefits against possible risks.
  • Renal impairment: no dosage adjustment required, but monitor renal function.
  • Concomitant ACE inhibitors: may increase bradykinin levels; monitor for enhanced angioedema.
  • Hypersensitivity: discontinue immediately if an allergic reaction occurs.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Icatibant may interact with other medicines. Review the following interaction categories:

Major Interactions (Avoid)

  • ACE inhibitors: may reduce therapeutic effectiveness and increase angioedema risk.
  • Other bradykinin B2 antagonists: additive pharmacologic effect; avoid simultaneous use.
  • C1‑inhibitor concentrates given concurrently: may interfere with intended action.

Moderate Interactions (Monitor Closely)

  • NSAIDs: can potentiate angioedema; monitor for swelling.
  • Estrogen‑containing contraceptives: may exacerbate hereditary angioedema; observe closely.
  • Diuretics: may affect fluid balance; watch for hypotension.

Frequently Asked Questions

Icatibant Stada is used to treat acute attacks of hereditary angioedema (HAE) type I and type II. It works by rapidly reducing swelling caused by excess bradykinin, helping to relieve symptoms such as facial, peripheral, and airway edema.

Icatibant blocks the bradykinin B2 receptor, preventing bradykinin from triggering vasodilation and increased vascular permeability. By inhibiting this pathway, the drug limits the fluid leakage that leads to the swelling seen in hereditary angioedema attacks.

The dose of Icatibant Stada is determined by the prescribing healthcare professional based on the patient’s condition and clinical guidelines. The prescriber will decide the exact amount and frequency of administration.

Safety data for Icatibant Stada in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and this decision must be made by a qualified clinician.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed), and import documentation.

Icatibant is a selective bradykinin B2 receptor antagonist, whereas other options such as C1‑esterase inhibitor concentrates replace a missing protein, and newer monoclonal antibodies target different pathways. Icatibant offers rapid subcutaneous administration, making it convenient for emergency self‑treatment.

Icatibant Stada should be stored at 2‑8 °C (refrigerated). Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution to maintain its stability.

The medication is supplied as a solution for injection and is given subcutaneously, typically into the abdomen or thigh. A healthcare professional or trained patient can perform the injection using the supplied device, following the prescriber’s instructions.

Serious risks include anaphylaxis, airway angioedema that can compromise breathing, severe hypotension, and rare cases of necrosis at the injection site. Patients should seek immediate medical attention if they experience any signs of a severe allergic reaction or airway swelling.

Individuals with known hypersensitivity to icatibant or any component of the formulation should avoid its use. Caution is also advised for patients receiving ACE inhibitors or other bradykinin‑modulating agents, and those with uncontrolled cardiovascular conditions should be evaluated by a physician before treatment.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Icatibant

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT